The land beyond price targets Price targets are an animal I’ve never really taken seriously. This artificially created number gets taken as a realistic goal for many investors,…
Taylor Gavinchuk
Magnifying the problem When lockdowns first hit back in March 2020 I was pretty sure the capital markets and the psychedelic sector would suffer. It was a burgeoning…
The system is broken During the pandemic, almost everyone I have talked to is dealing with some sort of mental health breakdown or deterioration since the pandemic started….
Generic neoliberal bullshit Look, I’m not a fan of Joe Biden, but I’m also not a ‘Joe Biden has soup for brains’ guy. I don’t think he’s stupid,…
OG status There are many ways to stay ahead of the game in terms of picking stocks, and if timing is everything then getting in early into companies…
New clinical trials are emerging in the psychedelics sector at a rapid pace. Several compounds are being studied for their efficacy in treating ailments like PTSD, depression, anxiety, and…
Pubco failure Microdosing was the biggest buzzword in the psychedelics sector only 2 years ago, but nowadays it’s rarely discussed, at least in terms of publicly traded companies. HAVN…
Fear & Loathing There’s several debates raging about which specific psychedelics to get behind, investors are trying to guess which ones will provide the necessary breakthroughs within the medical…
The strongest vertical? Ketamine One Capital (MEDI.NE), a company name that probably would have turned heads only 1 or 2 years ago, but now makes total sense is on…
“Suicide Opportunity” I can’t remember what company it was, maybe MindMed, but one of their early pitch decks had a page titled ‘Suicide Opportunity’. Yesterday I wrote an…